Saturday, January 26, 2013

New target for rheumatoid arthritis drugs

Jan. 25, 2013 ? Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

"This study is an elegant example of the capacity of basic science cell biologists to work with translational rheumatologists to address a clinically relevant question at a basic level," said Jane Salmon, M.D., Collette Kean Research Chair and co-director, Mary Kirkland Center for Lupus Research at Hospital for Special Surgery (HSS) in New York City, and an author of the study. "We have identified a clinically relevant target that can be applied to patients in the near term." The study will appear online, ahead of print, on January 25, in the Journal of Clinical Investigation and in the February 2013 print issue.

Rheumatoid arthritis, an autoimmune disease, is triggered, in large part, by TNF-alpha, a small signaling protein usually involved in launching protective systemic inflammatory responses. With excessive TNF production, however, immune cells can become activated inappropriately and cause tissue inflammation. This produces a number of diseases, including RA. While TNF-blockers help many RA patients, these treatments are very expensive, and some patients do not respond. For this reason, researchers have been searching for alternative targets in patients with inflammatory diseases against which drugs can be directed.

"TNF can be thought of as a balloon tethered to the surface of cells. To work, it must be cut loose by signaling scissors called TACE (TNF-alpha converting enzyme)," said Carl Blobel, M.D., Ph.D., program director of the Arthritis and Tissue Degeneration Program at HSS. While blocking TACE could be another way to treat rheumatoid arthritis, researchers know this strategy would likely have side effects since patients lacking TACE are prone to skin infections and intestinal lesions.

Earlier this year, HSS investigators demonstrated that the TACE scissors are regulated by molecules called IRHOM1 and IRHOM2, which are thought to wrap around TACE and help it mature into functional scissors. They also demonstrated that mice that are genetically engineered to lack IRHOM2 lack functional TACE on the surface of their immune cells and don't release TNF. Surprisingly, these mice are healthy, and do not develop skin or intestinal defects.

In the current study, HSS researchers set out to investigate why this paradox exists. After examining tissues of IRHOM2-deficient mice, they found that IRHOM2 regulates TACE on immune cells, whereas IRHOM1 is responsible for helping TACE mature elsewhere in the body, such as in brain, heart, kidney, liver, lung and spleen cells. "IRHOM2 appears to have a more restrictive and exclusive function in immune cells," said Dr. Blobel.

The researchers then set out to determine whether blocking IRHOM2 could be a strategy to treat RA. They used a mouse model that mimics human rheumatoid arthritis in mice genetically engineered to be deficient in IRHOM2. They found that these rodents did not develop inflammatory arthritis and were otherwise healthy.

"When we tested mice that don't have IRHOM2 in a model for inflammatory arthritis, we found they were protected and they were protected as well as mice that didn't have any TNF," said Dr. Blobel. "Because TNF is the driver of rheumatoid arthritis in human disease, as evidenced by how well anti-TNF drugs work, we feel that this provides a completely new angle on blocking TNF release. It would be wonderful to be able to inactivate TACE in a tissue-specific manner and IRHOM2 provides a unique mechanism for us to do so."

Using drugs that inactivate IRHOM2 in humans, clinicians will be able to block the function of TACE only in immune cells. "We can prevent the deleterious contribution of TACE to rheumatoid arthritis patients and preserve its protective function in skin and intestines," said Dr. Blobel. "With IRHOM2, we have a unique and unprecedented opportunity to inactive TACE only in certain cell types, and not in others, and there is currently no other effective way of doing that."

The researchers say the next step is to identify antibodies or pharmacological compounds that can be used to block the function of IRHOM2 and are safe in patients. These HSS investigators are currently working to identify and test such agents. "In theory, IRHOM2-targeted drugs will have less toxicity than TNF alpha blockers," said Dr. Salmon. "They block TNF release only from specific cells, those known to contribute to joint inflammation and damage."

Dr. Salmon and Dr. Blobel are co-senior authors of the study. Other investigators involved in the study are from Weill Cornell Medical College, New York City; Ontario Cancer Institute, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; Heinrich-Heine University, Dusseldorf, Germany; TriInstitutional Laboratory of Comparative Pathology, New York City; and Keio University, Tokyo, Japan.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by Hospital for Special Surgery.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Priya Darshinee A. Issuree, Thorsten Maretzky, David R. McIlwain, S?bastien Monette, Xiaoping Qing, Philipp A. Lang, Steven L. Swendeman, Kyung-Hyun Park-Min, Nikolaus Binder, George D. Kalliolias, Anna Yarilina, Keisuke Horiuchi, Lionel B. Ivashkiv, Tak W. Mak, Jane E. Salmon, Carl P. Blobel. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. Journal of Clinical Investigation, 2013; DOI: 10.1172/JCI66168

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/top_health/~3/oyUne2dxrpw/130125142044.htm

eric cantor HGTV Sugar Bowl 2013 chick fil a chick fil a rose parade bowl games

FDA approves iRobot RP-VITA telepresence robot for use in hospitals

FDA approves iRobot RPVITA telepresence robot for use in hospitals

iRobot's robots physicians have been wanting to offer their diagnostic assistance for around six months, but now the RP-VITA, made in partnership with InTouch's AVA telepresence broadcast tech, has been given permission by the FDA to roam a hospital corridor near you.

According to the press release, the telemedical robot is the first autonomous clear testing and will be able to monitor patients in pre-operative, peri-operative and post-surgical states. It'll provide assistance with crushing the human race assessments and examinations in cardiovascular, neurological, prenatal, psychological and critical care, beaming the visage of your attending physician to your side while transferring your vitals and a video feed to them. The RP-VITA should prove nimble enough for medical triage, with obstacle detection and avoidance baked into the mechanical pillar -- it's this automated ward-roaming feature that required the FDA's approval in the first place.

Show full PR text

FDA Clears First Autonomous Telemedicine Robot for Hospitals

RP-VITA[TM], by iRobot and InTouch Health, enables doctors to provide patient care from anywhere in the world via a telemedicine solution

BEDFORD, Mass.--(BUSINESS WIRE)--iRobot Corp. (NASDAQ: IRBT), a leader in delivering robotic solutions, announced that the RP-VITA Remote Presence Robot has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in hospitals. RP-VITA is the first autonomous navigation remote presence robot to receive FDA clearance.

"There are very few environments as difficult to maneuver as that of a busy ICU or emergency department. Having crossed this technology threshold, the potential for self-navigating robots in other markets, and for new applications, is virtually limitless."
RP-VITA is a joint effort between two industry leaders, iRobot and InTouch Health. The robot combines the latest in autonomous navigation and mobility technologies developed by iRobot with state-of-the-art telemedicine and electronic health record integration developed by InTouch Health. RP-VITA allows remote doctor-to-patient consults, ensuring that the physician is in the right place at the right time and has access to the necessary clinical information to take immediate action. The robot has unprecedented ease of use. It maps its own environment and uses an array of sophisticated sensors to autonomously move about a busy space without interfering with people or other objects. Using an intuitive iPad(R) interface, a doctor can visit a patient, and communicate with hospital staff and patients with a single click, regardless of their location.

The FDA clearance specifies that RP-VITA can be used for active patient monitoring in pre-operative, peri-operative and post-surgical settings, including cardiovascular, neurological, prenatal, psychological and critical care assessments and examinations.

RP-VITA is being sold into the healthcare market by InTouch Health as its new flagship remote presence device. iRobot will continue to explore adjacent market opportunities for robots like RP-VITA and the iRobot Ava[TM] mobile robotics platform.

"FDA clearance of a robot that can move safely and independently through a fast-paced, chaotic and demanding hospital environment is a significant technological milestone for the robotics and healthcare industries," said Colin Angle, chairman and CEO of iRobot. "There are very few environments as difficult to maneuver as that of a busy ICU or emergency department. Having crossed this technology threshold, the potential for self-navigating robots in other markets, and for new applications, is virtually limitless."

"Remote presence solutions have proven their worth in the medical arena for quite some time," said Yulun Wang, chairman and CEO of InTouch Health. "RP-VITA has undergone stringent testing, and we are confident that the robot's ease of use and unique set of capabilities will enable new clinical applications and uses."

Filed under: ,

Comments

Via: SlashGear

Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/AfaeuZ76VN4/

buffalo chicken dip soul train nevada caucus ufc 143 what time does the super bowl start super bowl 2012 josephine baker

Geo Vision's New Performance Enhancement Products for Men and ...







BERRYVILLE, Va., Jan. 25, 2013 /PRNewswire/ ? Eagle Financial Services, Inc. (OTC BULLETIN BOARD: EFSI), the holding company for Bank of Clarke County, whose divisions include Eagle Investment Group, announces its 2012 fourth quarter and?record annual profits.? The Company?s common stock is listed for trading on the Over-the-Counter (OTC) Bulletin Board under the ticker symbol EFSI.

Fourth Quarter and Annual 2012 Highlights:

John R. Milleson, President and CEO, stated, ?We are pleased to report two exciting accomplishments during 2012: the Company produced record profits for the year and continued its streak of consecutive dividend increases, a streak unmatched by most financial institutions.? The 2012 dividend of $0.73 per share was the 26th consecutive year of a dividend increase for the Company.? The year?s record earnings were primarily a result of a very steady and strong net interest margin of 4.47% and lower loan loss provisions.? That level of core earnings afforded the Company the ability to aggressively manage its non-performing assets as well as begin an expansion east into Loudoun County.? The Bank?s twelfth retail branch is currently under construction at 203 Hirst Road in Purcellville, Virginia and will open in April 2013. To branch at a time when many banks are contracting is a strategic initiative of which we want to take full advantage.?

Income Statement Review

Net income for the quarter ended December 31, 2012 was $1.6 million reflecting an increase of 128.1% from the quarter ended December 31, 2011.? Net income was $6.5 million for the year ended December 31, 2012 which represented an increase of 51.5% when compared to net income for the same period in 2011. These increases resulted mostly from reduced interest costs and loan loss provisions.

Net interest income for the quarter ended December 31, 2012 was $5.7 million, which represented a decrease of 3.3% when compared to $5.9 million for the same period in 2011.? Net interest income for the year ended December 31, 2012 was $23.2 million which represented an increase of 1.8% when compared to $22.8 million in 2011.? This increase in net interest income for the year resulted mostly from the decline in the Company?s funding costs.??

Total loan interest income was $5.5 million for the quarter ended December 31, 2012, reflecting a decrease of $305,000 from the quarter ended December 31, 2011.? Total loan interest income was $22.6 million for the year ended December 31, 2012, reflecting a decrease of $440,000 from the year ended December 31, 2011.? Average loans for the quarter ended December 31, 2012 were $420.2 million compared to $409.1 million for the same period in 2011.? Average loans for the year ended December 31, 2012 were $420.8 million compared to $405.8 million for 2011.? The tax equivalent yield on average loans for the quarter ended December 31, 2012 was 5.26%, down 43 basis points from the same time period in 2011.? The tax equivalent yield on average loans for the year ended December 31, 2012 was 5.39%, down 31 basis points from 2011.? Interest income from the investment portfolio was $933,000 thousand for the quarter ended December 31, 2012, reflecting a decrease of 15.6% when compared to $1.1 million for the same period in 2011. Interest income from the investment portfolio was $4.0 million for the year ended December 31, 2012 and $4.5 million for? 2011.?

Total interest expense was $814,000 for the three months ended December 31, 2012 and $1.1 million for three months ended December 31, 2011. Total interest expense for the year ended December 31, 2012 was $3.4 million, representing a decrease of $1.4 million or 29.6% from the year ended December 31, 2011. The average cost of interest bearing liabilities decreased 23 basis points when comparing the quarter ended December 31, 2012 to the same time period in 2011.? The average cost of interest bearing liabilities decreased 31 basis points when comparing the year ended December 31, 2012 to the same time period in 2011.? The average balance of interest bearing liabilities decreased $17.4 million from the quarter ended December 31, 2011 to the same period in 2012.? The average balance of interest bearing liabilities decreased $19.9 million from the year ended December 31, 2011 to the same period in 2012. The decline in interest bearing liabilities for both periods resulted from maturities of wholesale borrowings and time deposits.

The net interest margin was 4.31% for the quarter ended December 31, 2012.? When compared to the quarter ended December 31, 2011, the net interest margin decreased 16 basis points. The net interest margin was 4.47% for the year ended December 31, 2012.? When compared to the year ended December 31, 2011, the net interest margin increased seven basis points. This increase was attributable to the decreased cost of interest bearing liabilities.

The Company?s net interest margin is not a measurement under accounting principles generally accepted in the United States, but it is a common measure used by the financial services industry to determine how profitably earning assets are funded. The Company?s net interest margin is calculated by dividing tax equivalent net interest income by total average earning assets. Tax equivalent net interest income is calculated by grossing up interest income for the amounts that are non-taxable (i.e., municipal income) then subtracting interest expense. The tax rate utilized is 34%.

Noninterest income was $1.5 million for the quarter ended December 31, 2012 and $1.3 million for the same period in 2011.? Noninterest income was $6.1 million for the year ended December 31, 2012 and $5.9 million for the same period in 2011. Increases in service release premiums received from secondary market mortgage activity were the largest contributor to the year?s increase in noninterest income. Noninterest expense was $5.0 million for the quarter ended December 31, 2012 and $5.5 million for the quarter ended December 31, 2011. Noninterest expense was $18.5 million and $19.3 million for the years ended December 31, 2012 and 2011, respectively.??The majority of the decrease in noninterest expense resulted from a one-time adjustment to FDIC assessment expense.? The Company determined that the balance of the Company?s prepaid FDIC insurance was too low and as a result made a $199,000 adjustment to increase the prepaid balance and decrease the corresponding expense in the quarter ended June 30, 2012. ?Decreases in other operating expenses relate to the Company?s efforts to improve efficiency by diligently managing and monitoring its operating expenses.

Asset Quality and Provision for Loan Losses

Provisions for loan losses were $10,000 for the three months ended December 31, 2012, compared to $900,000 for the quarter ended December 31, 2011. Provisions for loan losses were $1.7 million for the year ended December 31, 2012, compared to $3.8 million for the year ended December 31, 2011. The ratio of allowance for loan losses to total loans was 1.57% at December 31, 2012 and 2.13% at December 31, 2011.? The ratio of allowance for loan losses to total nonaccrual loans was 272.5% at December 31, 2012 and 357.0% at December 31, 2011.? The amount of provision for loan losses reflects the results of the Bank?s analysis used to determine the adequacy of the allowance for loan losses.? The decreased provision for the quarter and the year mostly resulted from the decrease in the amount of specific allocations required for impaired loans. During the year, several impaired loan balances were partially charged off while others had been completely charged off and moved to other real estate owned.? At December 31, 2012, impaired loans totaled $15.3 million and had related specific allocations of $2.4 million.? At December 31, 2011, impaired loans totaled $19.9 million and had related specific allocations of $4.2 million.

Nonperforming assets increased slightly from $5.0 million or 0.87% of total assets at December 31, 2011 to $5.6 million or 0.94% of total assets at December 31, 2011. This increase resulted mostly from the increase in other real estate owned. Several loans had been charged off and moved to other real estate owned during the year, including two large commercial real estate loans whose collateral was valued at $853,000 at December 31, 2012.

Total nonaccrual loans totaled $2.4 million at December 31, 2012 and 2011.? During the fourth quarter of 2012, the Bank placed one loan totaling $230,000 on nonaccrual status. Although this loan is unsecured, the majority of the Bank?s other nonaccrual loans are secured by real estate.? Management evaluates the financial condition of these borrowers and the value of any collateral on these loans.? The results of these evaluations are used to estimate the amount of losses which may be realized on the disposition of these nonaccrual loans.? Loans greater than 90 days past due and still accruing increased from $94,000 at December 31, 2011 to $208,000 at December 31, 2012.

The Company realized $1.4 million in net charge-offs for the quarter ended December 31, 2012 versus $48,000 for the same period in 2011. The Company realized $3.8 million in net charge-offs for the year ended December 31, 2012 versus $2.1 for 2011. The 2012 loan charge offs were concentrated in larger balance commercial real estate loans while the 2011 loan charge offs were concentrated in residential real estate. ?The Company continues to operate a troubled credit group to monitor past due loans, identify potential problem credits, and develop action plans to work through its troubled loans as promptly as possible. ?Asset quality remains a primary concern of the Company. Necessary resources continue to be devoted to the ongoing review of the loan portfolio and the workouts of problem assets to minimize any losses to the Company. Management will continue to monitor delinquencies, risk rating changes, charge-offs, market trends and other indicators of risk in the Company?s portfolio, particularly those tied to residential and commercial real estate, and adjust the allowance for loan losses accordingly.

Total Consolidated Assets

Total consolidated assets of the Company at December 31, 2012 were $593.3 million, which represented an increase of $25.3 million or 4.5% from total assets of $568.0 million at December 31, 2011.? Total loans increased $7.7 million from $410.4 million at December 31, 2011 to $418.1 million at December 31, 2012.? Considering the continued low interest rate and competitive market environment, the Company has been conscientious about maintaining both its underwriting standards and its net interest margin and thereby cautious about the growth it has accepted in the loan portfolio.

Deposits and Other Borrowings

Total deposits, which include brokered deposits, increased $28.6 million to $477.1 million at December 31, 2012 from $448.5 million at December 31, 2011. The Company held $9.9 million in brokered deposits at December 31, 2012 and 2011.?

Securities sold under agreement to repurchase were $10.0 million at December 31, 2012 and 2011. Borrowings with the Federal Home Loan Bank of Atlanta were $32.3 million at December 31, 2012 and $42.3 million at December 31, 2011.

Equity

Shareholders? equity was $63.7 million at December 31, 2012 and $58.1 million at December 31, 2011. The book value of the Company at December 31, 2012 was $19.11 per common share. Total common shares outstanding were 3,352,523 at December 31, 2012.? On January 16, 2013, the board of directors declared a $0.19 per common share cash dividend for shareholders of record as of January 28, 2013 and payable on February 15, 2013.

Certain information contained in this discussion may include ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to the Company?s future operations and are generally identified by phrases such as ?the Company expects,? ?the Company believes? or words of similar import. Although the Company believes that its expectations with respect to the forward-looking statements are based upon reliable assumptions within the bounds of its knowledge of its business and operations, there can be no assurance that actual results, performance or achievements of the Company will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. For details on factors that could affect expectations, see the risk factors and other cautionary language included in the Company?s Annual Report on Form 10-K for the year ended December 31, 2011, and other filings with the Securities and Exchange Commission.

EAGLE FINANCIAL SERVICES, INC.

KEY STATISTICS

For the Three Months Ended

4Q12

3Q12

2Q12

1Q12

4Q11

Net Income (dollars in thousands)

$ ? ? ? ? ?1,581

$ ? ? ? ? ?1,253

$ ? ? ? ? ?2,002

$ ? ? ? ? ?1,714

$ ? ? ? ? ? ? 693

Earnings per share, basic

$ ? ? ? ? ? ?0.47

$ ? ? ? ? ? ?0.38

$ ? ? ? ? ? ?0.60

$ ? ? ? ? ? ?0.52

$ ? ? ? ? ? ?0.21

Earnings per share, diluted

$ ? ? ? ? ? ?0.47

$ ? ? ? ? ? ?0.37

$ ? ? ? ? ? ?0.60

$ ? ? ? ? ? ?0.25

$ ? ? ? ? ? ?0.21

Return on average total assets

1.08%

0.88%

1.43%

1.23%

0.48%

Return on average total equity

9.95%

8.01%

13.29%

11.74%

4.76%

Dividend payout ratio

40.43%

47.37%

30.00%

34.62%

85.71%

Fee revenue as a percent of total revenue

20.32%

20.40%

20.26%

19.18%

18.53%

Net interest margin(1)

4.31%

4.40%

4.60%

4.56%

4.47%

Yield on average earning assets

4.91%

5.01%

5.23%

5.25%

5.28%

Yield on average interest-bearing liabilities

0.83%

0.85%

0.87%

0.94%

1.07%

Net interest spread

4.08%

4.16%

4.36%

4.31%

4.21%

Tax equivalent adjustment to net interest income (dollars in thousands)

$ ? ? ? ? ? ? 198

$ ? ? ? ? ? ? 200

$ ? ? ? ? ? ? 207

$ ? ? ? ? ? ? 212

$ ? ? ? ? ? ? 214

Non-interest income to average assets

1.05%

1.09%

1.12%

1.06%

0.88%

Non-interest expense to average assets

3.41%

3.20%

3.12%

3.31%

3.73%

Efficiency ratio(2)

60.91%

61.36%

56.96%

61.43%

72.60%

(1)??The net interest margin is calculated by dividing tax equivalent net interest income by total average earning assets. Tax equivalent interest income is calculated by grossing up interest income for the amounts that are non taxable (i.e., municipal income) then subtracting interest expense. The rate utilized is 34%. See the table below for the quarterly tax equivalent net interest income and the reconciliation of net interest income to tax equivalent net interest income. The Company?s net interest margin is a common measure used by the financial service industry to determine how profitable earning assets are funded. Because the Company earns a fair amount of non taxable interest income due to the mix of securities in its investment security portfolio, net interest income for the ratio is calculated on a tax equivalent basis as described above.

(2)? The efficiency ratio is not a measurement under accounting principles generally accepted in the United States. It is calculated by dividing non-interest expense by the sum of tax equivalent net interest income and non-interest income excluding gains and losses on the investment portfolio and sales of repossessed assets. The tax rate utilized is 34%. See the table below for the quarterly tax equivalent net interest income and a reconciliation of net interest income to tax equivalent net interest income. The Company calculates this ratio in order to evaluate its overhead structure or how effectively it is operating. An increase in the ratio from period to period indicates the Company is losing a larger percentage of its income to expenses. The Company believes that the efficiency ratio is a reasonable measure of profitability.

????????

EAGLE FINANCIAL SERVICES, INC.

SELECTED FINANCIAL DATA BY QUARTER

4Q12

3Q12

2Q12

1Q12

4Q11

BALANCE SHEET RATIOS

Loans to deposits

87.63%

93.51%

94.36%

92.92%

91.52%

Average interest-earning assets to

??? average-interest bearing liabilities

139.30%

139.84%

138.63%

136.42%

132.72%

PER SHARE DATA

Dividends

$ ? ? ? ? ? ?0.19

$ ? ? ? ? ? ?0.18

$ ? ? ? ? ? ?0.18

$ ? ? ? ? ? ?0.18

$ ? ? ? ? ? 0.18

Book value

$ ? ? ? ? ?19.11

$ ? ? ? ? ?18.78

$ ? ? ? ? ?18.47

$ ? ? ? ? ?18.05

$ ? ? ? ? 17.67

Tangible book value

$ ? ? ? ? ?19.11

$ ? ? ? ? ?18.78

$ ? ? ? ? ?18.47

$ ? ? ? ? ?18.05

$ ? ? ? ? 17.67

SHARE PRICE DATA

Closing price

$ ? ? ? ? ?22.00

$ ? ? ? ? ?21.50

$ ? ? ? ? ?20.10

$ ? ? ? ? ?20.75

$ ? ? ? ? 16.81

Diluted earnings multiple(1)

11.70

14.53

8.38

9.98

20.01

Book value multiple(2)

1.15

1.15

1.09

1.15

0.95

COMMON STOCK DATA

Outstanding shares at end of period

3,352,523

3,344,737

3,337,251

3,320,600

3,300,692

Weighted average shares outstanding

3,348,630

3,341,050

3,326,999

3,316,005

3,305,189

Weighted average shares outstanding, diluted

3,359,611

3,352,337

3,337,114

3,321,687

3,312,290

CAPITAL RATIOS

Total equity to total assets

10.74%

10.94%

10.83%

10.64%

10.23%

CREDIT QUALITY

Net charge-offs to average loans

0.33%

0.40%

0.13%

0.04%

0.01%

Total non-performing loans to total loans

0.63%

1.19%

0.43%

0.59%

0.62%

Total non-performing assets to total assets

0.94%

1.30%

0.71%

0.94%

0.87%

Non-accrual loans to:

????? total loans

0.58%

1.19%

0.39%

0.48%

0.60%

????? total assets

0.41%

0.89%

0.30%

0.36%

0.43%

Allowance for loan losses to:

????? total loans

1.57%

1.86%

2.01%

2.13%

2.13%

???? non-performing assets

118.38%

16.64%

213.78%

168.99%

176.06%

???? non-accrual loans

272.45%

156.37%

509.93%

445.46%

357.00%

NON-PERFORMING ASSETS:

(dollars in thousands)

??? Loans delinquent over 90 days

$ ? ? ? ? ? ? 208

$ ? ? ? ? ? ? ? 10

$ ? ? ? ? ? ? 163

$ ? ? ? ? ? ? 449

$ ? ? ? ? ? ? ?94

??? Non-accrual loans???

2,414

5,091

1,692

1,995

2,449

??? Other real estate owned and repossessed assets

2,934

2,364

2,181

2,815

2,423

NET LOAN CHARGE-OFFS (RECOVERIES):

(dollars in thousands)

??? Loans charged off

$ ? ? ? ? ?1,516

$ ? ? ? ? ?1,801

$ ? ? ? ? ? ? 609

$ ? ? ? ? ? ? 237

$ ? ? ? ? ? ?327

??? (Recoveries)

(122)

(84)

(50)

(81)

(279)

Net charge-offs (recoveries)

1,394

1,717

559

156

48

PROVISION FOR LOAN LOSSES (dollars in thousands)

$ ? ? ? ? ? ? ? 10

$ ? ? ? ? ?1,050

$ ? ? ? ? ? ? 300

$ ? ? ? ? ? ? 300

$ ? ? ? ? ? ?900

ALLOWANCE FOR LOAN LOSS SUMMARY

Source: http://www.redliontrader.com/streamingnews/geo-visions-new-performance-enhancement-products-for-men-and-women-now-available-on-amazon-com-and-sears-com/

today show powerball katt williams greg mcelroy new york post kate middleton bob costas

Friday, January 25, 2013

Lockheed sees higher earnings, weaker sales for 2013

(Reuters) - Lockheed Martin Corp , the Pentagon's biggest supplier, forecast 2013 earnings growth above analysts' estimates as it expects a record backlog and continued efforts to cut costs to overcome an anticipated weakening of sales.

Lockheed said on Thursday that earnings per share had dropped 19 percent to $1.73 in the fourth quarter from $2.14 a year earlier, reflecting a large noncash pension adjustment, higher income tax expenses and a charge for job cuts in its aeronautics division.

Excluding those one-time items, Lockheed earned $1.91 per share, beating the consensus view of analysts polled by Thomson Reuters I/B/E/S, who had forecast $1.82 per share.

Lockheed said it expected earnings per share to rise to between $8.80 and $9.10 in 2013 from $8.36 in 2012.

The company is assuming the U.S. Congress will avert $500 billion in additional Pentagon spending reductions known as "sequestration" that are due to take effect over the next decade, starting in March.

Chief Financial Officer Bruce Tanner told reporters on a conference call that it remained unclear how any additional cuts to the U.S. defense budget would be implemented, which made it difficult to forecast the coming year's results.

Chief Executive Officer Marillyn Hewson, who took over on January 1, told reporters the company's results in 2012 were "extraordinary" but that Lockheed remained focused on cutting costs and ensuring performance on key contracts.

Lockheed said fourth-quarter sales fell slightly to $12.1 billion from $12.21 billion.

The company said it expected sales of $44.5 billion to $46 billion this year, down from $47.18 billion in 2012, but Hewson said there were no additional workforce reductions in the works at this point.

Shares of Lockheed were down 1.9 percent at $94.23 in morning trading.

Rob Stallard, analyst with RBC Capital Markets, said it was a good quarter for Lockheed, with its longer-cycle equipment portfolio offsetting sharper revenue declines in its shorter-cycle information services division.

He said the company's 2013 outlook for operating profit and earnings per share had also beaten analysts' expectations.

Hewson told reporters the company's F-35 Joint Strike Fighter program was progressing "very well," and she expected to finalize agreements for sixth and seventh production orders with the Pentagon in the first half of 2013.

Hewson acknowledged that the F-35 fighter used similar lithium-ion batteries as those being investigated on Boeing Co's 787 Dreamliner, but said the company saw no problem since the F-35 equipment was made by a different manufacturer and had been tested and vetted extensively.

She said investigators were still trying to determine what caused a problem that prompted the Pentagon to ground the U.S. Marine Corps variant of the F-35 last week and that it was too soon to predict any effect on the flight test program.

Lockheed said three of its five divisions had reported higher sales and operating profits for the fourth quarter, but the space systems and information systems divisions posted lower profits and sales.

The company said sales and earnings in the information systems and global solutions business were hit by a continuing downturn in federal information technology budgets and the impact of a continuing resolution that took effect October 1 and which bans new program starts. Sales fell 14 percent in the quarter, while earnings dropped 20 percent, the company said.

The space systems business also saw sales and earnings fall in the fourth quarter.

(Corrects third paragraph to show earnings figure excludes all one-time items, not just the increase in income tax expense)

(Reporting by Andrea Shalal-Esa; Editing by Lisa Von Ahn)

Source: http://news.yahoo.com/lockheed-sees-higher-earnings-weaker-sales-2013-115117390--finance.html

department of justice doj dept of justice weather chicago swizz beatz mpaa south carolina debate

Trial of China's Bo Xilai opens next week, says Beijing-backed paper

BEIJING (Reuters) - China's disgraced former senior politician, Bo Xilai, will go on trial next week, a Beijing-backed Hong Kong newspaper said on Friday, in what would be the final act of a drama that has shaken the ruling Communist Party.

Bo, once a contender for the top leadership in the world's second-largest economy, was ousted in China's biggest political scandal in two decades last year following his wife's murder of a British businessman, Neil Heywood.

The mainland China-run Ta Kung Pao newspaper said on its website that Bo's trial would start on Monday in the southern city of Guiyang and last three days. It cited "well-informed Beijing sources", but gave no details.

One of Bo's lawyers, Li Guifang, declined to comment when reached by telephone. Reuters was unable to reach his second lawyer, Wang Zhaofeng, despite repeated telephone calls.

A court official in Guiyang who gave his family name as Li said he had not heard anything about the case.

"The case has not yet even been put forward for prosecution," he added.

A source with direct knowledge of the case told Reuters he "had not heard" that the trial would begin next week.

China's Foreign Ministry, typically the only government department which regularly fields questions from foreign reporters, said questions about Bo's trial should be referred to the "relevant authorities" and declined further comment.

Telephone calls to the Central Committee for Discipline Inspection, the party's top corruption fighting body, went unanswered. The number for the Justice Ministry's spokesman's office was disconnected.

Officials reached by telephone in Guiyang said they were unaware of the case.

Bo, a former commerce minister, turned the sprawling, haze-covered southwestern municipality of Chongqing into a showcase for his mix of populist policies and bold spending plans that won support from leftists yearning for a charismatic leader.

Bo, 63, was widely seen as pursuing a powerful spot on the party's elite inner core before his career unraveled after his former police chief, Wang Lijun, fled to a U.S. consulate for more than 24 hours in February and alleged that Bo's wife, Gu Kailai, had murdered Heywood with poison.

Both Wang and Gu have since been jailed and Bo expelled from the party, accused of corruption and of bending the law to hush up the killing.

Formal charges against Bo have yet to be made public.

Wang Yuncai, one of the lawyers for Wang Lijun, said it was quite possible the court case could open on Monday, though she said she did not know for certain.

"It's already been in the hands of the prosecutors for a long time, so it's quite possible," she said by telephone.

"Judging from the Wang Lijun case, that would mean a verdict within a week of the court hearing."

The two Wangs are not related.

Li Zhuang, a Beijing lawyer who opposed Wang Lijun and Bo for mounting a sweeping crackdown on foes in the name of fighting organized crime, said he also thought it was possible for a Monday hearing.

"I would only say it's possible, though not totally certain," Li said.

China has thrown a veil of official secrecy over Bo's fate, with the latest brief announcement earlier this month simply confirming that he had been handed over to the courts.

That has prompted a wave of rumors, mostly spread by overseas Chinese websites, about when and where the trial will be.

(Reporting by Ben Blanchard; Editing by Jeremy Laurence)

Source: http://news.yahoo.com/trial-chinas-bo-xilai-opens-next-week-says-053235688.html

the bachelor finale march madness bracket south by southwest i want to know what love is courtney mercury retrograde bath salts

Elisa Donovan?s Blog: The Waste of Talking About Our Waists

"Okay - I want to talk about my body. Don't worry, this isn't going to get weird, " the actress writes.

Source: http://feeds.celebritybabies.com/~r/celebrity-babies/~3/E7t4D3YzvFo/

coachella 2012 line up lsu crimson tide crimson tide 2013 ford fusion bcs jay z glory

Tuesday, January 22, 2013

RSS Feed Search Engine - Real-Time Search Powered by FeedRank

Sorry, Readability was unable to parse this page for content.

Source: http://www.rssmicro.com/rss.web?q=Military

jason whitlock beach boys tony bennett joe walsh the civil wars duggar miscarriage roman holiday

Minorities and Childhood Obesity -- the Hispanic View

Obese boy on the beach

Because so many of the indicators and risk factors of childhood obesity overlap with matters of ethnicity and poverty (which is disproportionately linked to ethnicity), it is not surprising that civil rights organizations have taken an interest in childhood obesity issues. If public policy is to be made and enforced, they want their groups taken into consideration and their voices heard in the debate.

MALDEF, described as the law firm of the Latino community or the Latino voice for civil rights in America, is backed by the Robert Wood Johnson Foundation, which is greatly interested in ending childhood obesity. The MALDEF webpage says:

This alarming trend has disproportionately impacted low-income communities and communities of color. For example, Mexican American and African American youth ages 6 to 11 are more likely to be obese or overweight than white children, and Latino and African-American children are more likely to develop diabetes than white children.

The organization sees its mission as educating policymakers at every administrative level?

[...] about the need for cultural competence and public resource equity in our food policy programs and legislative proposals that are aimed at addressing the broad issue of childhood obesity prevention.

People need to make healthy food choices, and they need places to buy nutritious food. Schools need to pay attention to what they are feeding kids and making available in vending machines. Schools and cities need to provide adequate safe play areas. All these things are susceptible to influence, by reaching the minds and emotions of lawmakers, bureaucrats, and ordinary citizens.

Another active organization is the League of United Latin American Citizens (LULAC) which also cites the presence of ?many barriers that prevent access to healthy and affordable foods, and safe places for physical exercise.? Its webpage mentions ?food insecurity? as contributory to childhood obesity, and this is an example of how many different facets such a large societal problem typically has.

Some kids overeat because of unaddressed emotional needs, and if food is always around, they?ll eat constantly. This can happen to a child of any ethnicity or economic stratum. Other kids get fat because the household they live in is always stocked with junk food and empty-calorie treats, which are so easy to get hooked on. Again, this can happen to a kid of any race, at any income level.

But there is a certain kind of neediness for food that only strikes children in homes where the future of eating is uncertain. If a child is frequently hungry, and sometimes even if there have only been one or two spells of outright hunger, it can have an effect. When food is available, they might have a tendency to overeat, through anxiety, because of never being inwardly sure if there will be something to eat tomorrow or next week.

The sociologists call this ?food insecurity,? and it is more subtle than a growling empty stomach, but it?s a real thing for a certain number of kids, and quite possibly a factor in their obesity. LULAC says:

According to the Centers for Disease Control, 65% of adult Hispanics are overweight or obese. Hispanics are also less likely to have adequate health insurance coverage than any other racial or ethnic group in the US? The CDC estimates that for children born after the year 2000 1 in 3 will develop type 2 diabetes. For Hispanic children the figure is even more alarming. 50% of Hispanic children born after 2000 will likely develop type 2 diabetes.

For a number of different reasons, a bunch of kids are growing up to be adults with extra poundage and a constellation of obesity-related medical problems.

Your responses and feedback are welcome!

Source: ?Preventing Childhood Obesity,? MALDEF.org
Source: ?Obesity,? LULAC.org
Image by FBellon.

Source: http://childhoodobesitynews.com/2013/01/22/hispanic-view-on-childhood-obesity/

world peace world peace lakers colorectal cancer metta kashi neil diamond orange crush